NGeneBio Co., Ltd. (KOSDAQ:354200)

Market Cap	24.69B -32.6%
Revenue (ttm)	31.20B +363.7%
Net Income	-7.00B
EPS	-291.13
Shares Out	26.81M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	73,000
Open	998.00
Previous Close	1,007.00
Day's Range	986.00 - 1,023.00
52-Week Range	968.00 - 2,765.00
Beta	0.75
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 14, 2026

About NGeneBio

NGeneBio Co., Ltd. develops in vitro diagnostics companion diagnostics products and bioinformatics software. It offers BRCAaccuTest and BRCAaccuTest PLUS are reagent kits for breast and ovarian cancer, and hereditary breast and ovarian cancer syndrome; HEMEaccuTest, a clinical NGS kit for hematological malignancies, such as acute myeloid leukemia, acute lymphoid leukemia, myelodysplastic/myeloproliferative neoplasm, multiple myeloma, and lymphoma; SOLIDaccuTest, a genetic variants screening for solid tumors; HLAaccuTest, an in vitro diagnostic ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2015
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 354200

Financial Performance

In 2025, NGeneBio's revenue was 21.24 billion, an increase of 278.54% compared to the previous year's 5.61 billion. Losses were -5.54 billion, -57.29% less than in 2024.